Prof. Dr. Christine Dierks

• kommissarische Direktorin
• leitende Oberärztin
• Personaloberärztin
• Leitung der Arbeitsgruppe Molekulare Krebstherapie
• Aufbau ECTU/Tagesklinik und einer experimentellen CAR-T Zell Unit

• Molekulare Krebstherapie bei soliden Tumoren
• Immuntherapien/CAR-T Zell Therapien
• Molekulares Tumorboard
• IIT Klinische Studien bei Schilddrüsenkarzinomen (ATLEP Trial) und CLL
• Endokrine Tumoren, Lymphome (CLL, T-Zell Lymphome), MPN

• Leukämische Stammzellen und die Stammzellnische
• Neue Therapeutische Targets bei der CLL und T-Zell Lymphomen
• Kinasen und embryonale Signalwege als neue Therapieansätze bei soliden Tumoren

2022

Paschold L, Simnica D, Benitez Brito R, Zhang T, Schultheiß C, Dierks C, Binder M. Subclonal heterogeneity sheds light on the transformation trajectory in IGLV3-21R110 chronic lymphocytic leukemia. Blood Cancer J. 2022 Mar 30;12(3):49. doi: 10.1038/s41408-022-00650-4.

Grimm J, Simnica D, Jäkel N, Paschold L, Willscher E, Schulze S, Dierks C, Al-Ali HK, Binder M. Azacitidine-induced reconstitution of the bone marrow T cell repertoire is associated with superior survival in AML patients. Blood Cancer J. 2022 Jan 28;12(1):19. doi: 10.1038/s41408-022-00615-7.

2020     

Dierks C, Seufert J, Aumann K, Ruf J, Klein C, Kiefer S, Rassner M, Boerries M, Zielke A, La Rosee P, Meyer PT, Kroiss M, Weissenberger C, Schumacher T, Metzger P, Weiss H, Smaxwil C, Laubner K, Duyster J, Bubnoff N, Miething C, Thomusch O.The Lenvatinib/Pembrolizumab combination is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma.Thyroid. 2020 accepted 

Szenes E, Härzschel A, Decker S, Tissino E, Pischeli J, Gutjahr JC, Kissel S, Pennisi S, Höpner JP, Egle A, Zaborsky N, Dierks C, Follo M, Chigaev A, Zucchetto A, Greil R, Gattei V, Hartmann TN. TCL1 transgenic mice as a model for CD49d-high chronic lymphocyticleukemia Leukemia. 2020 Sep;34(9):2498-2502. doi: 10.1038/s41375-020-0759-3.     

Fagnan A, Bagger FO, Piqué-Borràs MR, Ignacimouttou C, Caulier A, Lopez CK, Robert E, Uzan B, Gelsi-Boyer V, Aid Z, Thirant C, Moll U, Tauchmann S, Kurtovic-Kozaric A, Maciejewski J, Dierks C, Spinelli O, Salmoiraghi S, Pabst T, Shimoda K, Deleuze V, Lapillonne H, Sweeney C, De Mas V, Leite B, Kadri Z, Malinge S, de Botton S, Micol JB, Kile B, Carmichael CL, Iacobucci I, Mullighan CG, Carroll M, Valent P, Bernard OA, Delabesse E, Vyas P, Birnbaum D, Anguita E, Garçon L, Soler E, Schwaller J, Mercher T. Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers. Blood. 2020 Aug 6;136(6):698-714. doi: 10.1182/blood.2019003062.                            

Kreutmair S, Erlacher M, Andrieux G, Istvanffy R, Mueller-Rudorf A, Zwick M, Rückert T, Pantic M, Poggio T, Shoumariyeh K, Mueller TA, Kawaguchi H, Follo M, Klingeberg C, Wlodarski M, Baumann I, Pfeifer D, Kulinski M, Rudelius M, Lemeer S, Kuster B, Dierks C, Peschel C, Cabezas-Wallscheid N, Duque-Afonso J, Zeiser R, Cleary ML, Schindler D, Schmitt-Graeff A, Boerries M, Niemeyer CM, Oostendorp RA, Duyster J, Illert AL. Loss of the Fanconi anemia-associated protein NIPA causes bone marrow failure. J Clin Invest. 2020 Jun 1;130(6):2827-2844. doi: 10.1172/JCI126215.          

2019

Decker S, Zwick A, Khaja Saleem S, Kissel S, Rettig A, Aumann K, Dierks C. Optimized xenograft protocol for chronic lymphocytic leukemia results in high engraftment efficiency for all CLL subgroups.  Int J Mol Sci. 2019 Dec 12;20(24).

Müller TA, Zwick A, Decker S, Klein C, Rister B, Rudorf A, Kissel S, Follo M, Wäsch R, Illert AL, Oostendorp R, Waskow C, Dierks C*, Duyster J*. * contributed equally, Dierks corresponing author PIM1 inhibition effectively enhances plerixafor-induced HSC mobilization by counteracting CXCR4 upregulation and blocking CXCL12 secretion. Leukemia, 2019 Feb 28. doi: 10.1038/s41375-019-0428-6

2018

Jutzi JS, Kleppe M, Dias J, Staehle HF, Shank K, Teruya-Feldstein J, Gambheer SMM, Dierks C, Rienhoff HY Jr, Levine RL, Pahl HL. LSD1 Inhibition Prolongs Survival in Mouse Models of MPN by Selectively Targeting the Disease Clone. Hemasphere. 2018 Jun 8;2(3):e54.

Prestipino A, Emhardt AJ, Aumann K, O'Sullivan D, Gorantla SP, Duquesne S, Melchinger W, Braun L, Vuckovic S, Boerries M, Busch H, Halbach S, Pennisi S, Poggio T, Apostolova P, Veratti P, Hettich M, Niedermann G, Bartholomä M, Shoumariyeh K, Jutzi JS, Wehrle J, Dierks C, Becker H, Schmitt-Graeff A, Follo M, Pfeifer D, Rohr J, Fuchs S, Ehl S, Hartl FA, Minguet S, Miething C, Heidel FH, Kröger N, Triviai I, Brummer T, Finke J, Illert AL, Ruggiero E, Bonini C, Duyster J, Pahl HL, Lane SW, Hill GR, Blazar BR, von Bubnoff N, Pearce EL, Zeiser R. Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms.SciTransl Med. 2018 Feb 21;10(429).                                                                           

Simon-Gabriel CP, Foerster K, Saleem S, Bleckmann D, Benkisser-Petersen M, Thornton N, Umezawa K, Decker S, Burger M, Veelken H, Claus R, Dierks C, Duyster J, Zirlik K. Microenvironmentalstromal cells abrogate NF-κB inhibitor-induced apoptosis in chronic lymphocytic leukemia.Haematologica. 2018 Jan;103(1):136-147.            

Hoefflin, R.,Geißler, A.-L., Fritsch, R., Claus, R.,,Wehrle, J., Metzger, P., Reiser, M., Mehmed, L., Fauth, L., Heiland, D.H., Erbes, T., Stock, F.,,Csanadi, A., Miething, C., Weddeling, B., Meiss, F., von Bubnoff, D., Dierks, C., Ge, I., Brass, V., Heeg, S., Schäfer, H., Boeker, M., Rawluk, J., Botzenhart, E.M., Kayser, G., Hettmer, S., Busch, H., Peters, C., Werner, M., Duyster, J., Brummer, T., Boerries, M., Lassmann, S. and von Bubnoff, N. (2018). Personalized clinical decision making through implementation of a Molecular Tumorboard – a German single centre experience.JCO Precision Oncology, August 16, 2018

2016

Klein C, Zwick A, Kissel S, Decker S, Benkler T, Pahl H, Oostendorp R, Duyster J,  Dierks C.Ptch2 loss drives myeloproliferation and MPN progression. J Exp Med. 2016 Feb 8;213(2):273-90                          

Herrtwich L, Nanda I, Evangelou K, Nikolova T, Horn V, Sagar, Erny D, Stefanowski J, Rogell L, Klein C, Gharun K, Follo M, Seidl M, Kremer B, Münke N, Senges J, Fliegauf M, Aschman T, Pfeifer D, Sarrazin S, Sieweke MH, Wagner D, Dierks C, Haaf T, Ness T, Zaiss MM, Voll RE, Deshmukh SD, Prinz M, Goldmann T, Hölscher C, Hauser AE, Lopez-Contreras AJ, Grün D, Gorgoulis V, Diefenbach A, Henneke P, Triantafyllopoulou A. DNA Damage Signaling Instructs Polyploid Macrophage Fate in Granulomas. Cell. 2016 Nov 17;167(5):1264-1280.e18. doi: 10.1016/j.cell.2016.09.054.    

Benkisser-Petersen M, Buchner M, Dörffel A, Dühren-von-Minden M, Claus R, Kläsener K, Leberecht K, Burger M, Dierks C, Jumaa H, Malavasi F, Reth M, Veelken H, Duyster J, Zirlik K. Spleen Tyrosine Kinase Is Involved in the CD38 Signal Transduction Pathway in Chronic Lymphocytic Leukemia. PLoSOne. 2016 Dec 30;11(12):e0169159. 

2014

Decker S, Finter J, Forde AJ, Kissel S, Schwaller J, Mack TS, Kuhn A, Gray N, Follo M, Jumaa H, Burger M, Zirlik K, Pfeifer D, Miduturu CV, Eibel H, Veelken H, Dierks C. Dual role of PIM kinases in CLL: PIM1 regulates CXCR4 surface expression and  PIM 2/3 CLL cell survival. MolCancer Ther. 2014 May;13(5):1231-45.    

Sprissler C, Belenki D, Maurer H, Aumann K, Pfeifer D, Klein C, Müller TA, Hülsdünker J, Alexandrowski J, Brummer T, Jumaa H, Duyster J, Dierks C. Depletion of STAT5 blocks TEL-SYK induced APMF-type leukemia with myelofibrosis and myelodysplasia in mice Blood Cancer Journal, 2014 August; 22;4:e240.

Bach MP, Hug E, Werner M, Holch J, Sprissler C, Pechloff K, Zirlik K, Zeiser R, Dierks C, Ruland J, Jumaa H. Premature terminal differentiation protects from deregulated lymphocyte activation by ITK-Syk. J Immunol. 2014 Feb 1;192(3):1024-33.

2013

Jutzi JS, Bogeska R, Nikoloski G, Schmid CA, Seeger TS, Stegelmann F, Schwemmers S, Gründer A, Peeken JC, Gothwal M, Wehrle J, Aumann K, Hamdi K, Dierks C, Kamar Wang W, Döhner K, Jansen JH, Pahl HL. MPN patients harbor recurrent truncating mutations in transcription factor NF-E2.  J Exp Med. 2013 May 6;210(5):1003-19.

Brault L, Rovó A, Decker S, Dierks C, Tzankov A, Schwaller J. CXCR4-SERINE339 regulates cellular adhesion, retention and mobilization, and is a marker for poor prognosis in acute myeloid leukemia. Leukemia. 2013 Jul 2. doi: 10.1038/leu.2013.201

Yaktapour N, Ubelhart R, Schüler J, Aumann K, Dierks C, Burger M, Pfeifer D, Jumaa H, Veelken H, Brummer T, Zirlik K. Insulin-like growth factor-1 receptor (IGF1R) as a novel target in chronic lymphocytic leukemia. Blood. 2013 Aug 29;122(9):1621-33.

2012

Decker S, Zirlik K, Djebatchie L, Hartmann D, Ihorst G, Schmitt-Graeff A, Herchenbach D, Jumaa H,   Warmuth M, Veelken H, Dierks C. Trisomy 12 and elevated GLI1 and PTCH1 transcript levels are biomarkers for Hedgehog-inhibitor responsiveness in CLL. Blood. 2012 Jan 26;119(4):997-1007. Epub 2011 Nov 30.        

2010          

Zhang J, Adrián FJ, Jahnke W, Cowan-Jacob SW, Li AG, Iacob RE, Sim T, Powers J, Dierks C, Sun F, Guo GR, Ding Q, Okram B, Choi Y, Wojciechowski A, Deng X, Liu G, Fendrich G, Strauss A, Vajpai N, Grzesiek S, Tuntland T, Liu Y, Bursulaya B, Azam M, Manley PW, Engen JR, Daley GQ, Warmuth M, Gray NS. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature. 2010 Jan 28;463(7280):501-6 

Buchner M, Baer C, Prinz G, Burger M, Zenz T, Stilgenbauer S, Dierks C, Jumaa H, Veelken H, Zirlik K. Spleen Tyrosine Kinase Inhibition Prevents Chemokine- and Integrin-Mediated Stromal Protective Effects in ghznb Lymphocytic Leukemia. Blood. 2010 Jun 3;115(22):4497-506 

Brantner P, Stickel N, Prinz G, Burger M, Bär C, Dierks C, Pfeifer D, Ott A, Mertelsmann R, Gribben JG, Veelken H, Zirlik K. The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukaemia - CXCR4 antagonists as potential adjuvants for monoclonal antibodies.  British Journal of Haematology, 2010 151(2):167-78  

Dierks C, Adrian F, Ma H, Guo G, Zirlik K, Stegert M, Beigi R, Veelken H,  Warmuth M.  ITK-SYK induces T-cell lymphomas in mice mimicking human disease. Cancer Res. 2010 Aug 1;70(15):6193-204

2009

Buchner M, Fuchs S, Prinz G, Pfeifer D, Bartholomé K, Chevalier N, Vallat L, Timmer J, Gribben JG, Jumaa H, Veelken H, DierksC*, Zirlik K*. Spleen Tyrosine Kinase (SYK) is Overexpressed and Represents a Potential Therapeutic Target in Chronic Lymphocytic Leukemia. *contributed equallyCancer Res. 2009 Jul 1;69(13):5424-32        

Grundler R, Gasser C, Brault L, Bullock AN, Dechow T, Nawjin M, Berns A, Woetzel S, Pogacic V, Ehret S, Berridge G, Spoo A, Dierks C, Biondi A, Knapp S, Duyster J, Schwaller J. PIM kinases in FLT3-ITD-mediated leukemia: unravelling of an essential function of PIM1 in early bone marrow homing and functional interaction with the SDF1α/CXCR4 axis. J Exp Med. 2009 Aug 31;206(9):1957-70

2008

Dierks C, Beigi R, Stegert M, Zirlik K, Guo G, Schmitt-Graeff A, Veelken H, Warmuth M. Hedgehog signaling is essential for expansion of Bcr-Abl positive leukemic stem cells. Cancer Cell. 2008 Sep 9;14(3):238-49

2007

Dierks C, Grbic J, Zirlik K, Beigi R, Englund NP, Veelken H, Engelhardt M, Mertelsmann R, Kelleher J, Schultz P, Warmuth M. Essential role of stromally induced hedgehog signalling in B-cell malignancies. Nat. Med. 2007, 13: 944-951

2003

Schuster C (now Dierks C), Forster K, Dannhauser-Riedl S, Hallek M,  Warmuth M. The effects of Bcr-Abl on C/EBP transcription-factor regulation and neutrophilic differentiation are reversed by the Abl kinase inhibitor imatinib mesylate. Blood, 2003 Jan 15;101(2):655-63